196 related articles for article (PubMed ID: 36052474)
41. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma.
Carli M; Colombatti R; Oberlin O; Stevens M; Masiero L; Frascella E; Koscielniak E; Treuner J; Pinkerton CR
J Clin Oncol; 1999 Sep; 17(9):2796-803. PubMed ID: 10561355
[TBL] [Abstract][Full Text] [Related]
42. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
Crist WM; Anderson JR; Meza JL; Fryer C; Raney RB; Ruymann FB; Breneman J; Qualman SJ; Wiener E; Wharam M; Lobe T; Webber B; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Jun; 19(12):3091-102. PubMed ID: 11408506
[TBL] [Abstract][Full Text] [Related]
43. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
Dantonello TM; Int-Veen C; Harms D; Leuschner I; Schmidt BF; Herbst M; Juergens H; Scheel-Walter HG; Bielack SS; Klingebiel T; Dickerhoff R; Kirsch S; Brecht I; Schmelzle R; Greulich M; Gadner H; Greiner J; Marky I; Treuner J; Koscielniak E
J Clin Oncol; 2009 Mar; 27(9):1446-55. PubMed ID: 19224858
[TBL] [Abstract][Full Text] [Related]
44. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
45. Phase II trial of ifosfamide in children with malignant solid tumors.
Pratt CB; Horowitz ME; Meyer WH; Etcubanas E; Thompson EI; Douglass EC; Wilimas JA; Hayes FA; Green AA
Cancer Treat Rep; 1987 Feb; 71(2):131-5. PubMed ID: 3100034
[TBL] [Abstract][Full Text] [Related]
46. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
47. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
Donfrancesco A; Jenkner A; Castellano A; Ilari I; Milano GM; De Sio L; Cozza R; Fidani P; Deb G; De Laurentis C; Inserra A; Dominici C
Acta Paediatr Suppl; 2004 May; 93(445):6-11. PubMed ID: 15176712
[TBL] [Abstract][Full Text] [Related]
48. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study.
Duffner PK; Krischer JP; Horowitz ME; Cohen ME; Burger PC; Friedman HS; Kun LE
Ann Neurol; 1998 Sep; 44(3):313-6. PubMed ID: 9749596
[TBL] [Abstract][Full Text] [Related]
49. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study.
Castleberry RP; Cantor AB; Green AA; Joshi V; Berkow RL; Buchanan GR; Leventhal B; Mahoney DH; Smith EI; Hayes FA
J Clin Oncol; 1994 Aug; 12(8):1616-20. PubMed ID: 8040674
[TBL] [Abstract][Full Text] [Related]
50. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
[TBL] [Abstract][Full Text] [Related]
51. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Womer RB; West DC; Krailo MD; Dickman PS; Pawel BR; Grier HE; Marcus K; Sailer S; Healey JH; Dormans JP; Weiss AR
J Clin Oncol; 2012 Nov; 30(33):4148-54. PubMed ID: 23091096
[TBL] [Abstract][Full Text] [Related]
52. Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma.
Massimino M; Gandola L; Luksch R; Spreafico F; Riva D; Solero C; Giangaspero F; Locatelli F; Podda M; Bozzi F; Pignoli E; Collini P; Cefalo G; Zecca M; Casanova M; Ferrari A; Terenziani M; Meazza C; Polastri D; Scaramuzza D; Ravagnani F; Fossati-Bellani F
Neuro Oncol; 2005 Jan; 7(1):41-8. PubMed ID: 15701281
[TBL] [Abstract][Full Text] [Related]
53. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S
Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622
[TBL] [Abstract][Full Text] [Related]
54. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
[TBL] [Abstract][Full Text] [Related]
55. Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Osawa S; Kumabe T; Saito R; Sonoda Y; Niizuma H; Watanabe M; Tominaga T
Brain Tumor Pathol; 2011 Apr; 28(2):167-74. PubMed ID: 21210238
[TBL] [Abstract][Full Text] [Related]
56. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR
Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486
[TBL] [Abstract][Full Text] [Related]
57. Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology.
Stewart RJ; Martelli H; Oberlin O; Rey A; Bouvet N; Spicer RD; Godzinski J; Stevens MC;
J Clin Oncol; 2003 Mar; 21(5):793-8. PubMed ID: 12610176
[TBL] [Abstract][Full Text] [Related]
58. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.
Kushner BH; Kramer K; LaQuaglia MP; Modak S; Yataghene K; Cheung NK
J Clin Oncol; 2004 Dec; 22(24):4888-92. PubMed ID: 15611504
[TBL] [Abstract][Full Text] [Related]
59. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
[TBL] [Abstract][Full Text] [Related]
60. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
